# US 2021/0330654 A1 · Agent for treating or preventing glaucoma including a sulfonamide compound and another drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330654 A1
- Document ID: US20210330654A1
- Status: Published application
- Kind: A1
- Application number: 17/358,883
- Filed: 2021-06-25
- Published: 2021-10-28
- Earliest claimed: 2012-07-13
- Assignees: Santen Pharmaceutical Co., Ltd.
- Applicants: Santen Pharmaceutical Co., Ltd.
- Inventors: Tomoko KIRIHARA; Atsushi SHIMAZAKI; Masatsugu NAKAMURA
- Web page: https://patentgrep.com/patent/US20210330654A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/225: Polycarboxylic acids
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 401/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

## Claims

### Claim 1

A preventive or therapeutic agent for glaucoma or ocular hypertension, comprising a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

### Claim 2 (depends on 1)

The preventive or therapeutic agent according to claim 1, wherein the other preventive or therapeutic drug for glaucoma or ocular hypertension is one or more preventive or therapeutic agents selected from the group consisting of a nonselective sympathomimetic drug, an α2-receptor agonist, an α1-receptor antagonist, a β-receptor antagonist, a parasympathomimetic drug, a carbonic anhydrase inhibitor, a prostaglandin and a Rho-kinase inhibitor.

### Claim 3 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the nonselective sympathomimetic drug is dipivefrin.

### Claim 4 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the α2-receptor agonist is brimonidine or apraclonidine.

### Claim 5 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the α1-receptor antagonist is bunazosin.

### Claim 6 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the β-receptor antagonist is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

### Claim 7 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the parasympathomimetic drug is pilocarpine.

### Claim 8 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the carbonic anhydrase inhibitor is dorzolamide, brinzolamide or acetazolamide.

### Claim 9 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

### Claim 10 (depends on 2)

The preventive or therapeutic agent according to claim 2, wherein the Rho-kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl) benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

### Claim 11

An intraocular pressure lowering agent comprising a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

### Claim 12 (depends on 11)

The intraocular pressure lowering agent according to claim 11, wherein the other preventive or therapeutic drug for glaucoma or ocular hypertension is one or more preventive or therapeutic agents selected from the group consisting of a nonselective sympathomimetic drug, an α2-receptor agonist, an α1-receptor antagonist, a β-receptor antagonist, a parasympathomimetic drug, a carbonic anhydrase inhibitor, a prostaglandin and a Rho-kinase inhibitor.

### Claim 13 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the nonselective sympathomimetic drug is dipivefrin.

### Claim 14 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the α2-receptor agonist is brimonidine or apraclonidine.

### Claim 15 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the α1-receptor antagonist is bunazosin.

### Claim 16 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the β-receptor antagonist is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

### Claim 17 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the parasympathomimetic drug is pilocarpine.

### Claim 18 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the carbonic anhydrase inhibitor is dorzolamide, brinzolamide or acetazolamide.

### Claim 19 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost.

### Claim 20 (depends on 12)

The intraocular pressure lowering agent according to claim 12, wherein the Rho-kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl) benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.
